QPPV.COM KNOWLEDGE ASSESSMENT

Ivacaftor: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Ivacaftor: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A child receiving ivacaftor granules develops increased transaminases after a respiratory infection and a new antibiotic. What is the best pharmacovigilance follow-up approach?
Question 2 of 10 A caregiver reports that a child receives the wrong granule strength and sometimes takes doses without the required food. Which principle is most relevant?
Question 3 of 10 A patient taking ivacaftor reports diarrhoea during a period of worsening CF gastrointestinal symptoms. Which assessment principle is most appropriate?
Question 4 of 10 A patient taking ivacaftor has worsening respiratory symptoms and little apparent benefit. Which assessment best addresses possible lack of effectiveness?
Question 5 of 10 A case intake form records only the term ivacaftor for a patient who may be receiving a fixed combination. Which follow-up information is most important to clarify the exposure?
Question 6 of 10 A laboratory assay suggests that a CFTR variant responds to ivacaftor. Which conclusion is most professionally justified?
Question 7 of 10 Which conclusion is best supported by the STRIVE trial in participants aged at least 12 years with a G551D variant?
Question 8 of 10 Why is evidence supporting ivacaftor use in very young children not simply equivalent to the adult spirometric evidence?
Question 9 of 10 A patient taking a combination regimen reports that an evening ivacaftor dose was omitted. Which case interpretation is most appropriate?
Question 10 of 10 A patient has two class I variants known not to produce CFTR protein. Which interpretation is most consistent with the article's discussion of combination eligibility?

Select an answer to continue.

QPPV.com